Thursday, October 19, 2017 10:15 PM ET
Insider at KalVista Pharmaceuticals (KALV) Makes Significant purchase of Stock Reverses Sale Trend of Last Quarter
There was substantial buying activity in KalVista Pharmaceuticals shares by an insider today, as disclosed in a form 4 document filed with the SEC. One insider — Richard Aldrich, Director — acquired 565,065 shares in the company having a market value of approximately $4,866,961. There have been 3 insiders with buy/sell transactions in the past 90 days prior to this filing. These trades have resulted in the acquisition of 1,700,000 company shares and the disposition of 2,901,930 company shares over this time period. Adding the most recent activity to this 90-day history indicates insider trades have been net sales of 636,865 shares and have averaged 1,291,749 shares per transaction over this time period.
Insider buy/sell trading at KalVista Pharmaceuticals is higher than the 42 peer company average over the last 90-day period. The Biopharmaceuticals peer group saw 29 buy/sell trades during this period for an average of 0.7 transactions per company. The number of shares per buy/sell trade for KalVista Pharmaceuticals insiders was also higher. Within the peer group there were 1,744,500 shares purchased and 3,717,484 shares sold with company insiders disposing of 68,034 shares on average.
The data obtained in composing and writing in this story eliminates all trading activity reported to the SEC that involves awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers.
Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.
For more information, contact UpTick at firstname.lastname@example.org. Copyright 2017 UpTick Data Technologies. All rights reserved.